Polymorphism of the biotransformation gene cytochrome-450 2C9 in patients with tuberculosis

The aim of the present work was to investigate cytochrome-450 (CYP) 2C9 (CYP2C9) gene polymorphism in patients with tuberculosis (TB) and its meaning for the development, course, and outcome of TB and for pharmacokinetics of antituberculosis antibiotic rifampicin on the basis of the southern region of Ukraine. Among TB patients, there were 24.9% fewer carriers of the genotype *1/*1 than in healthy donors; at the same time, there are 25.0% more carriers of the genotype *1/*2, *1/*3. In TB patients with the genotype *2/*3, *3/*3 the level of rifampicin in blood was the highest. At the beginning of treatment in carriers of the genotype *1/*1, pulmonary destruction was observed 2.5 times more often than in the *1/*2, *1/*3 genotype. According to the cultural method, carriers of *1/*1 more frequently became smear-negative than those of the *1/*2, *1/*3 genotype.